List of FDA-Approved Peptides: Complete Guide 2026

The list of FDA-approved peptides has never been more relevant — or more misunderstood. With the 2026 FDA reclassification changing which compounds are legally available, knowing the difference between a truly FDA-approved peptide and a research compound matters more than ever.

Key Takeaways

• FDA approval signals clinical validation and regulatory oversight — separating proven therapeutics from unproven compounds
• Semaglutide (Ozempic/Wegovy) and tirzepatide (Zepbound/Mounjaro) are the most widely used FDA-approved peptides, both approved for weight management and type 2 diabetes
• Research peptides like BPC-157, CJC-1295, and GHK-Cu are not FDA-approved drugs — some have returned to legal compounding status in 2026, which is not the same thing
• FDA approval doesn't mean risk-free — it means clinical data supports safety at approved doses for specific indications
• Always verify FDA status directly and work with a licensed medical provider, especially when sourcing from compounding pharmacies or international suppliers

Contents

• What Does It Mean When a Peptide Is FDA-Approved?
• What Is the Complete List of FDA-Approved Peptides for Medical Use?
• Are Semaglutide and Tirzepatide on the List of FDA-Approved Peptides?
• What Is the FDA Approval Process for Peptides?
• How Do FDA-Approved Peptides Differ From Research Peptides?
• Are There FDA-Approved Peptides for Anti-Aging or Longevity?
• Where Can You Get FDA-Approved Peptides Safely?
• Frequently Asked Questions

FDA approval separates clinically validated peptide therapeutics from unproven research compounds — a distinction that matters more in 2026 than ever before.

What Does It Mean When a Peptide Is FDA-Approved?

A peptide earns FDA approval only after completing multi-phase clinical trials demonstrating safety and efficacy for a specific medical indication. This process typically spans 10–15 years and costs hundreds of millions of dollars — which is exactly why the list of FDA-approved peptide drugs is far shorter than the list of peptides people actually use.

FDA approval applies to a specific drug product, a specific indication, and a specific dose range. It doesn't mean the peptide is universally safe for all uses — it means clinical data supports safety and effectiveness for the approved application.

There's a critical distinction worth understanding: a peptide can be "FDA-approved" as a prescription drug (like Ozempic), or it can be a compound legally available through compounding pharmacies under a different regulatory framework. These are not the same designation.

Key insight: "FDA-approved" is not a blanket safety stamp. It's a statement that rigorous clinical trial data supports specific uses at specific doses. A peptide approved for type 2 diabetes isn't automatically proven for every weight loss protocol at every dose level.

When the FDA approves a peptide drug, it certifies three things: the drug works for its stated indication (efficacy), the benefits outweigh the known risks (safety), and the manufacturing process is consistent and controlled (quality). Physicians may still prescribe FDA-approved drugs "off-label" — legally, but without the same evidentiary foundation.

What Is the Complete List of FDA-Approved Peptides for Medical Use?

The FDA-approved peptide list includes dozens of compounds spanning oncology, endocrinology, diabetes management, and rare disease treatment. For the wellness, metabolic health, and performance contexts where most users encounter peptides, the most relevant approved compounds are the GLP-1 receptor agonists, GHRH analogs, and certain therapeutic peptides.

Here are the most clinically relevant FDA-approved peptides by category:

Peptide	Brand Name(s)	Approved Indication	Year Approved
Semaglutide	Ozempic, Wegovy, Rybelsus	Type 2 diabetes, weight management	2017, 2021
Tirzepatide	Mounjaro, Zepbound	Type 2 diabetes, weight management	2022, 2023
Tesamorelin	Egrifta	HIV-associated lipodystrophy	2010
Teriparatide	Forteo	Osteoporosis	2002
Exenatide	Byetta, Bydureon	Type 2 diabetes	2005
Liraglutide	Victoza, Saxenda	Type 2 diabetes, obesity	2010, 2014
Dulaglutide	Trulicity	Type 2 diabetes	2014
Octreotide	Sandostatin	Acromegaly, carcinoid tumors	1988
Oxytocin	Pitocin	Labor induction, postpartum	1950s
Vasopressin	Vasostrict	Vasodilatory shock	2014

This isn't an exhaustive pharmacological list — the FDA drug database contains hundreds of peptide-based compounds across every medical specialty. The table above focuses on compounds most relevant to metabolic health, body composition, and the performance contexts where users most commonly encounter peptide discussions.

Semaglutide and tirzepatide represent the most commercially validated FDA-approved peptides today, with combined revenues exceeding $30 billion in 2024.

Are Semaglutide and Tirzepatide on the List of FDA-Approved Peptides?

Yes — semaglutide and tirzepatide are both fully FDA-approved peptide drugs. Semaglutide received FDA approval in 2017 (Ozempic for diabetes) and 2021 (Wegovy for weight management). Tirzepatide was approved in 2022 (Mounjaro for diabetes) and 2023 (Zepbound for weight loss). Both require a prescription and are not legally available without medical oversight.

Semaglutide is a GLP-1 receptor agonist — it mimics a gut hormone that regulates insulin secretion, slows gastric emptying, and reduces appetite. Tirzepatide is a dual GLP-1/GIP agonist with a broader hormonal mechanism and stronger weight loss data.

By the numbers: Semaglutide's STEP trials showed 15–17% body weight reduction over 68 weeks. Tirzepatide's SURMOUNT trials demonstrated up to 22.5% weight loss — the highest ever recorded in a pharmaceutical weight management trial.

One important caveat: as of 2026, most compounded semaglutide has been phased out as FDA shortage designations lifted, and compounded tirzepatide is similarly being restricted. Sourcing either without a licensed pharmacy label and valid prescription means you're not using an FDA-approved product.

For a detailed breakdown of what to expect on semaglutide week by week — including side effects by phase — see Ozempic side effects: what to expect and how to manage them.

What Is the FDA Approval Process for Peptides?

The FDA approval pathway for peptides follows the same multi-phase clinical trial structure as all drugs: preclinical research, Phase I safety trials, Phase II efficacy trials, Phase III large-scale confirmatory trials, and regulatory review. The entire process averages 10–15 years — which is why the FDA-approved peptide list is short despite the thousands of compounds being studied.

Here's how each phase works:

• Preclinical: Animal studies establish basic safety, mechanism of action, and starting dose estimates
• Phase I: Small human trials (20–100 participants) test safety and identify dose tolerability
• Phase II: Larger trials (100–300 participants) test efficacy and identify side effect profiles
• Phase III: Large-scale trials (1,000–10,000+ participants) confirm efficacy and detect rare adverse events
• FDA Review: Full data submission; standard review takes 10–12 months
• Post-Market Surveillance: Ongoing Phase IV monitoring after approval

This gap between "peptides people discuss" and "FDA-approved peptides" is not accidental — the bar is intentionally high.

FDA drug approval requires 10–15 years of phased clinical trials — distinguishing approved therapeutics from compounds that are still in early research stages.

What About the 2026 Reclassification?

In February 2026, the US Health Secretary announced that 14 previously restricted peptides — including BPC-157, GHK-Cu, Epitalon, AOD-9604, and MOTS-c — would return to legal compounding status. This is significant regulatory news, but it's not the same as FDA drug approval.

Compounding pharmacies can now legally prepare these compounds for specific patients under physician supervision. But these peptides have not undergone the full Phase I–III clinical trial pathway required for FDA drug approval. Legal compounding eligibility is a regulatory accommodation — not a clinical endorsement.

How Do FDA-Approved Peptides Differ From Research Peptides?

FDA-approved peptides have completed phased clinical trials with thousands of human participants, establishing a clear safety and efficacy profile for a defined medical indication. Research peptides have animal studies and preliminary human data — some are in active clinical trials — but lack the full clinical trial record required for FDA drug status. The evidence base, quality controls, and legal framework are fundamentally different.

Here's a direct comparison:

Factor	FDA-Approved Peptide	Research Peptide
Human trial data	Extensive (Phase I–III completed)	Limited or animal-only
Regulatory status	Prescription drug	Research use; some available via compounding
Manufacturing standards	Pharmaceutical GMP required	Varies widely by source
Dose guidance	Clinically validated range	Based on community data and case reports
Insurance coverage	Often covered	Never covered
Physician guidance	Standard of care	Off-label or gray area

BPC-157, for example, has compelling animal studies showing accelerated healing and significant anti-inflammatory effects. Human case reports exist and are growing. But there are no completed Phase III human trials — which is why it sits firmly in the research category despite widespread use. To understand how BPC-157 actually performs over a real protocol timeline, see how long does BPC-157 take to work.

Bottom line: Research peptides aren't inherently dangerous — but the lower evidence bar means more uncertainty about optimal dosing, long-term effects, and compound purity from any given supplier. What clinical data shows about FDA-approved compounds took decades and billions of dollars to establish.

What Are Category 1 and Category 2 Peptides?

These are FDA compounding pharmacy classifications — not drug approval categories:

• Category 1: Compounds FDA has determined are appropriate for patient-specific compounding
• Category 2: Compounds that may be used in compounding but require additional safety review before widespread availability

The 2026 reclassification moved 14 peptides back toward Category 1 compounding eligibility. This is a legal accommodation for medical providers — not a statement of clinical validation comparable to full FDA drug approval.

Are There FDA-Approved Peptides for Anti-Aging or Longevity?

No peptide currently has FDA approval specifically for anti-aging or longevity. The FDA does not recognize "anti-aging" as an approved medical indication. Peptides commonly used for longevity — including GHK-Cu, Epitalon, MOTS-c, and Thymosin Alpha-1 — are research compounds without FDA drug approval, though many have returned to legal compounding status in 2026.

This doesn't mean these compounds are ineffective — it means the clinical evidence base is at an earlier stage. Most longevity peptide research is observational or animal-based, with a growing body of human case reports and early-phase trials.

Tesamorelin (Egrifta) is the closest FDA-approved peptide to longevity applications — a GHRH analog approved for HIV-associated lipodystrophy, also used off-label for body composition and metabolic health.

Key insight: "No FDA approval for anti-aging" doesn't mean these peptides are ineffective. It often means no pharmaceutical company funded a $500M trial for a compound that can't be easily patented. The evidence gap reflects economics as much as biology.

Where Can You Get FDA-Approved Peptides Safely?

Work with a licensed medical provider to verify FDA status and ensure you're receiving pharmaceutical-grade peptides from a legitimate, regulated source.

FDA-approved peptides like semaglutide and tirzepatide are available exclusively by prescription through licensed physicians and licensed pharmacies. Research peptides available through compounding pharmacies also require a physician prescription and verification of compounding pharmacy legitimacy. Sourcing any peptide without a prescription from online vendors significantly increases quality and dosing risk.

Here's how to source responsibly at each tier:

1. Prescription FDA-approved drugs (Ozempic, Wegovy, Zepbound): Work with your primary care physician, endocrinologist, or a weight management specialist. Telehealth platforms specializing in metabolic health can also prescribe.

2. Compounded peptides (BPC-157, Sermorelin, GHK-Cu, etc.): Require a physician's prescription at a licensed 503A or 503B compounding pharmacy. FDA-registered 503B outsourcing facilities have significantly higher quality and testing standards.

3. Gray-market online suppliers: FDA testing has found that up to 40% of online peptide products contained incorrect dosages or undeclared ingredients. Without pharmaceutical-grade manufacturing standards, potency and purity cannot be verified.

Once you have a legitimate medically-backed peptide protocol, administration technique is equally important. For a complete guide on safe self-administration, see where to inject peptides: complete guide to injection sites and technique and the detailed subcutaneous injection guide: how to self-administer peptides safely for step-by-step protocol.

Bottom line: "Legal" and "FDA-approved" are not the same thing. A compounded peptide from a licensed pharmacy is legal for the specific patient it's prescribed to — but it is not an FDA-approved drug. This distinction is how you evaluate risk accurately and make medically supervised peptide decisions.

Get Started with PeptideIQ

Whether you're tracking an FDA-approved GLP-1 protocol or navigating the more complex world of research peptides available through compounding, having a structured system separates successful protocols from costly guesswork. PeptideIQ is the AI-powered guided system built specifically for peptide users — protocol setup, dose logging with injection site rotation, an AI co-pilot that knows your specific cycle, and bloodwork tracking integrated in one place.

Join the PeptideIQ Waitlist

Frequently Asked Questions

What are the most common FDA-approved peptides prescribed today?

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the most widely prescribed FDA-approved peptide drugs today. Other common examples include liraglutide (Victoza, Saxenda), tesamorelin (Egrifta), teriparatide (Forteo), exenatide (Byetta), and dulaglutide (Trulicity). All require a prescription and active physician oversight.

What peptides can doctors legally prescribe?

Physicians can prescribe any FDA-approved peptide drug for its approved indication or off-label. They can also order compounded peptides — including BPC-157, Sermorelin, GHK-Cu, and others — from licensed compounding pharmacies for specific patients. The legal framework allows significant latitude when proper medical supervision and a valid patient-specific prescription are in place.

Is BPC-157 FDA-approved?

No. BPC-157 is not FDA-approved as a drug. It's a research peptide with strong animal trial data and growing human case reports but no completed Phase III human trials. Following the February 2026 policy change, BPC-157 returned to legal compounding status — meaning a physician can now prescribe it through a licensed compounding pharmacy — but this is not the same as FDA drug approval.

What is the difference between a Category 1 and Category 2 peptide?

Category 1 and Category 2 are FDA compounding classifications, not drug approval categories. Category 1 peptides are deemed appropriate for compounding. Category 2 peptides require additional FDA safety review before compounding is permitted. Neither category is equivalent to FDA drug approval, which requires completed Phase I–III clinical trials with thousands of human participants.

Are compounded peptides FDA-approved?

No. Compounded peptides are legally prepared by licensed pharmacies for specific patients under physician supervision, but they are not FDA-approved drug products. They do not go through the full Phase I–III clinical trial process. Quality and potency vary significantly by compounding facility — FDA-registered 503B outsourcing facilities provide the highest and most consistently tested manufacturing standards.

What peptide does Joe Rogan use?

Joe Rogan has publicly discussed using BPC-157 as part of his recovery stack for tendinitis, describing it as part of his "Wolverine stack." BPC-157 is a research peptide — not FDA-approved as a drug — but it returned to legal compounding status following the 2026 policy change. Rogan's discussions drove a significant spike in search interest and mainstream awareness of research peptides.

How do I verify whether a peptide I'm buying is legitimate?

For FDA-approved drugs like semaglutide and tirzepatide, only accept product dispensed from a licensed pharmacy with a valid prescription label. For compounded peptides, verify your pharmacy is a registered 503A or 503B facility using the FDA's public database. Any online seller claiming "FDA approval" for research peptides without referencing a specific brand-name approved drug is misrepresenting its regulatory status.